GA SNF ABBEVILLE GA LLC and GA SNF EASTMAN GA LLC acquires Selectis Health, Inc. for USD 15,700,000 (2026)

Deal facts

Buyer: GA SNF ABBEVILLE GA LLC and GA SNF EASTMAN GA LLC
Target: Selectis Health, Inc.
Deal value: USD 15,700,000
Announced: 7 May 2026
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

SEC_EDGAR_8K

What we know

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

1 May 2026CompletedClosed
GA SNF ABBEVILLE GA LLC and GA SNF EASTMAN GA LLC completes acquisition of Selectis Health, Inc.
Item 2.01 Completion of Acquisition or Disposition of Assets. On May 1, 2026, certain wholly-owned subsidiaries (collectively the “Sellers”) of Selectis Health, Inc. (the “Company”) GLOBAL ABBEVILLE PROPERTY, LLC and DODGE NH, LLC, each a Georgia limited liability company, consummated a definitive Purchase and Sale Agreement (“PSA”) with GA SNF ABBEVILLE GA LLC and GA SNF EASTMAN GA LLC, both limi
Source

OpinionExit Mode editorial

We see a clear signal in the completion of the asset sale of Selectis Health, Inc. by two newly formed US entities, GA SNF ABBEVILLE GA LLC and GA SNF EASTMAN GA LLC. The deal, announced on 7 May 2026 and valued at 15.7 million USD, is a straightforward cash transaction within the US healthcare sector. This structure is not merely a change of ownership but a deliberate operational reset. By choosing an asset sale over a share purchase, the buyers have likely sought to isolate specific liabilities while retaining the core clinical or administrative assets they value. For the SME founder in the UK watching this transatlantic move, the mechanics matter as much as the headline price.

The use of a pure cash consideration in an asset deal often points to a desire for speed and certainty, bypassing the complexities of share exchange or deferred payment structures. In the healthcare sector, this approach frequently triggers specific change-of-control covenants with key payers or regulatory bodies that require immediate notification or approval. While the deal is marked as completed, the underlying regulatory context in the US means that competition authorities or health service regulators would have scrutinised the transfer of patient data and service contracts. The buyers have taken on the burden of re-establishing these relationships, a risk that the seller effectively shed by selling assets rather than the corporate shell.

Our view is that this transaction highlights a growing trend where private equity or specialist operators prefer to carve out specific business units to avoid inheriting legacy liabilities. The clean break offered by an asset sale can be attractive to founders who have built a valuable operation but face a complex corporate history. However, this route demands rigorous due diligence on the assets being transferred to ensure no hidden obligations follow the buyer. The simplicity of the cash deal should not mask the operational friction that comes with transferring contracts and staff under a new legal entity.

You should review your own customer and supplier contracts this week to identify any change-of-control clauses that could be triggered by a future asset sale. Map out which assets are essential to your valuation and which liabilities you would prefer to leave behind, so you can structure a potential exit that mirrors the certainty seen in this US healthcare deal.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More asset sale deals More from GA SNF ABBEVILLE GA LLC and GA SNF EASTMAN GA LLC All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

14 October 2026Firm intentionHealthcare

Laboratory Corporation of America Holdings to acquire BioReference Health, LLC

Laboratory Corporation of America Holdings has agreed to acquire BioReference Health, LLC in a transaction valued at 722 million US dollars. The deal, announced on 14 Oc…

Buyer: Laboratory Corporation of America Holdings
Target: BioReference Health, LLC
Deal value: USD 722,000,000
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

14 October 2026CompletedHealthcare

Silo Pharma, Inc. to acquire Larry King

Silo Pharma, Inc. has completed the acquisition of assets from Larry King. The transaction, which was announced on 14 October 2026, was finalized on 13 October 2026. Bot…

Buyer: Silo Pharma, Inc.
Target: Larry King
Deal value: Not disclosed
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

2 October 2026Firm intentionHealthcare

Silo Pharma, Inc. to acquire Norsight Consulting Inc.

Silo Pharma, Inc. has agreed to acquire assets from Norsight Consulting Inc. in a transaction announced on 2 October 2026. Both companies are based in the United States…

Buyer: Silo Pharma, Inc.
Target: Norsight Consulting Inc.
Deal value: Not disclosed
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

1 October 2026CompletedHealthcare

JOINT Corp to acquire The Joint Franchises San Antonio, LLC, The Joint Franchises DFW, LLC, The Joint Franchises Houston, LLC, The Joint Franchises Austin, LLC, and The Joint Franchises Texas, Ltd.

JOINT Corp has agreed to acquire a portfolio of five Texas-based entities from The Joint franchise network. The transaction, announced and completed on 1 October 2026, i…

Buyer: JOINT Corp
Target: The Joint Franchises San Antonio, LLC, The Joint Franchises DFW, LLC, The Joint Franchises Houston, LLC, The Joint Franchises Austin, LLC, and The Joint Franchises Texas, Ltd.
Deal value: USD 8,000,000
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

30 September 2026Firm intentionHealthcare

Element Biosystems, LLC to acquire Standard BioTools Inc.

Element Biosystems, LLC has agreed to acquire Standard BioTools Inc. in a cash asset sale. The transaction was announced on 30 September 2026 and is valued at five milli…

Buyer: Element Biosystems, LLC
Target: Standard BioTools Inc.
Deal value: USD 5,500,000
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

Buyer history